For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of this treatment and the formulated version represents a genuine advancement . These groundbreaking therapies protect the transthyretin protein, slowing its damaging build-up and reducing th